[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100362125":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":10,"centralContacts":26,"locations":32,"responsibleParty":53,"collaborators":57,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":10,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Yale University","OTHER",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Schizophrenia and other psychotic disorders",null,"For each \\[11C\\]APP311 PET scan, up to 20 mCi of \\[11C\\]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.",[13],"Drug: [11C]APP311",{"label":15,"type":10,"description":11,"interventionNames":16},"Cannabis Use Disorder",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Healthy Control",[13],[21],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"DRUG","[11C]APP311","It has been shown that radiotracer \\[11C\\]APP311 (aka \\[11C\\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.",[15,18,9],[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Angerlyk Frytz, MD","CONTACT","203-974-7822","angerlyk.frytz@yale.edu",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Conneticut Mental Health Center","RECRUITING","New Haven","Connecticut","06519","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-72.92816,41.30815,{"lat":45,"lon":44},[48],{"name":49,"role":29,"phone":50,"phoneExt":51,"email":52},"Deepak C D'Souza, MD","203-932-5711","2594","deepak.dsouza@yale.edu",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Deepak C. D'Souza","Professor of Psychiatry",[58],{"name":59,"class":60},"National Institute on Drug Abuse (NIDA)","NIH","100362125","sv2-pet-imaging-with-11capp311-100362125",false,"NCT03995121","SV2 PET Imaging With [11C]APP311","Synaptic Density in Psychiatric Disorders Using SV2A Receptor PET Imaging With [11C]APP311","SV2","Inclusion Criteria:\n\n* Willing and able to give voluntary written informed consent\n* Male and Female subjects, age 18 to 65 years, inclusive\n\nExclusion Criteria:\n\n* MRI metal exclusions and claustrophobia.\n* Education completed is less than 12 years",true,"ALL","18 Years","85 Years",{"count":74,"type":75},250,"ESTIMATED","OBSERVATIONAL","The aim of this study is to evaluate a new SV2A tracer, \\[11C\\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.",[79,15,80],"Schizophrenia and Other Psychotic Disorders","Healthy","2026-01-26",{"date":83,"type":84},"2026-01-28","ACTUAL",{"date":86,"type":84},"2017-12-01",{"date":88,"type":75},"2026-12",{"name":5,"class":6},1]